|
1
|
Tsai RY and McKay RD: A nucleolar
mechanism controlling cell proliferation in stem cells and cancer
cells. Genes Dev. 16:2991–3003. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu SJ, Cai ZW, Liu YJ, Dong MY, Sun LQ,
Hu GF, et al: Role of nucleostemin in growth regulation of gastric
cancer, liver cancer and other malignancies. World J Gastroenterol.
10:1246–1249. 2004.PubMed/NCBI
|
|
3
|
Liu RL, Xu Y, Zhang ZH, Wang M, Sun JT, Qi
SY, et al: Expression of nucleostemin in prostate cancer tissues
and its clinical significance. Zhonghua Nan Ke Xue. 14:418–422.
2008.(In Chinese).
|
|
4
|
Zhang GY, Yin L, Li SL, Xing WY, Zhao QM,
Le XP, et al: Expression of nucleostemin mRNA and protein in the
esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi.
30:125–128. 2008.(In Chinese).
|
|
5
|
Sijin L, Ziwei C, Yajun L, Meiyu D,
Hongwei Z, Guofa H, et al: The effect of knocking-down nucleostemin
gene expression on the in vitro proliferation and in vivo
tumorigenesis of HeLa cells. J Exp Clin Cancer Res. 23:529–538.
2004.PubMed/NCBI
|
|
6
|
Ma H and Pederson T: Depletion of the
nucleolar protein nucleostemin causes G1 cell cycle arrest via the
p53 pathway. Mol Biol Cell. 18:2630–2635. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu RL, Zhang ZH, Zhao WM, Wang M, Qi SY,
Li J, et al: Expression of nucleostemin in prostate cancer and its
effect on the proliferation of PC-3 cells. Chin Med J (Engl).
121:299–304. 2008.PubMed/NCBI
|
|
8
|
Hsu JK, Lin T and Tsai RY: Nucleostemin
prevents telomere damage by promoting PML-IV recruitment to
SUMOylated TRF1. J Cell Biol. 197:613–624. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yue BH, Yu LN and Wang YY: Effects of
silent nucleostemin gene expression on apoptosis of HL-60 cells in
vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 17:319–323. 2009.(In
Chinese).
|
|
10
|
Beekman C, Nichane M, De Clercq S, Maetens
M, Floss T, Wurst W, et al: Evolutionarily conserved role of
nucleostemin: controlling proliferation of stem/progenitor cells
during early vertebrate development. Mol Cell Biol. 26:9291–9301.
2006. View Article : Google Scholar
|
|
11
|
Jafamejad SM, Mowla SJ and Matin MM:
Knocking-down the expression of nucleostemin significantly
decreases rate of proliferation of rat bone marrow stromal stem
cells in an apparently p53-independent manner. Cell Prolif.
41:28–35. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nikpour P, Mowla SJ, Jafarnejad SM,
Fischer U and Schulz WA: Differential effects of Nucleostemin
suppression on cell cycle arrest and apoptosis in the bladder
cancer cell lines 5637 and SW1710. Cell Prolif. 42:762–769. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu R, Zhang Z and Xu Y: Downregulation of
nucleostemin causes G1 cell cycle arrest via a p53-independent
pathway in prostate cancer PC-3 cells. Urol Int. 85:221–227. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zwolinska AK, Heagle WA, Beekman C, Sedivy
JM and Marine JC: Suppression of Myc oncogenic activity by
nucleostemin haploinsufficiency. Oncogene. 31:3311–3321. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paridaen JT, Janson E, Utami KH, Pereboom
TC, Essers PB, van Rooijen C, et al: The nucleolar GTP-binding
proteins Gnl2 and nucleostemin are required for retinal
neurogenesis in developing zebrafish. Dev Biol. 355:286–301. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vandermoere F, El Yazidi-Belkoura I,
Adriaenssens E, Lemoine J and Hondermarck H: The antiapoptotic
effect of fibroblast growth factor-2 is mediated through nuclear
factor-kappaB activation induced via interaction between Akt and
IkappaB kinase-beta in breast cancer cells. Oncogene. 24:5482–5491.
2005. View Article : Google Scholar
|
|
19
|
Zanotto-Filho A, Delgado-Cañedo A,
Schröder R, Becker M, Klamt F and Moreira JC: The pharmacological
NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and
apoptosis in leukemia cells through ROS-mitochondria pathway
activation. Cancer Lett. 288:192–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105
|
|
21
|
Haura EB, Turkson J and Jove R: Mechanisms
of disease: Insights into the emerging role of signal transducers
and activators of transcription in cancer. Nat Clin Pract Oncol.
2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dagvadorj A, Kirken RA, Leiby B, Karras J
and Nevalainen MT: Transcription factor signal transducer and
activator of transcription 5 promotes growth of human prostate
cancer cells in vivo. Clin Cancer Res. 14:1317–1324. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen CL, Cen L, Kohout J, Hutzen B, Chan
C, Hsieh FC, et al: Signal transducer and activator of
transcription 3 activation is associated with bladder cancer cell
growth and survival. Mol Cancer. 7:782008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaymaz BT, Selvi N, Saydam G, Sahin F and
Kosova B: Methylprednisolone induces apoptosis by interacting with
the JAK/STAT pathway in HL-60 and K-562 leukemic cells. Hematology.
17:93–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Busca R, Abbe P, Mantoux F, Aberdam E,
Peyssonnaux C, Eychène A, et al: Ras mediates the cAMP-dependent
activation of extracellular signal-regulated kinases (ERKs) in
melanocytes. EMBO J. 19:2900–2910. 2000. View Article : Google Scholar
|
|
27
|
Huang D, Ding Y, Luo WM, Bender S, Qian
CN, Kort E, et al: Inhibition of MAPK kinase signaling pathways
suppressed renal cell carcinoma growth and angiogenesis in vivo.
Cancer Res. 68:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ji Z, Flaherty KT and Tsao H: Targeting
the RAS pathway in melanoma. Trends Mol Med. 18:27–35. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Daouti S, Wang H, Li WH, Higgins B,
Kolinsky K, Packman K, et al: Characterization of a novel
mitogen-activated protein kinase kinase 1/2 inhibitor with a unique
mechanism of action for cancer therapy. Cancer Res. 69:1924–1932.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Su JC, Lin KL, Chien CM, Lu CM, Chen YL,
Chang LS and Lin SR: Novel indoloquinoline derivative, IQDMA,
induces G(2)/M phase arrest and apoptosis in A549 cells through
JNK/p38 MAPK signaling activation. Life Sci. 85:505–516. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brosseau CM, Pirianov G and Colston KW:
Involvement of stress activated protein kinases (JNK and p38) in
1,25 dihydroxyvitamin D3-induced breast cell death. Steroids.
75:1082–1088. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Uehara N, Kanematsu S, Miki H, Yoshizawa K
and Tsubura A: Requirement of p38 MAPK for a cell-death pathway
triggered by vorinostat in MDA-MB-231 human breast cancer cells.
Cancer Lett. 315:112–121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Romanova L, Grand A, Zhang L, Rayner S,
Katoku-Kikyo N, Kellner S, et al: Critical role of nucleostemin in
pre-rRNA processing. J Biol Chem. 284:4968–4977. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Romanova L, Kellner S, Katoku-Kikyo N and
Kikyo N: Novel role of nucleostemin in the maintenance of nucleolar
architecture and integrity of small nucleolar ribonucleoproteins
and the telomerase complex. J Biol Chem. 284:26685–26694. 2009.
View Article : Google Scholar : PubMed/NCBI
|
